Advertisement
Financing › Details
Danaher–SEVERAL: investment, 201106 public offering $905.625m+90.56m via 17.5m+1.75m shares of common stock $51.75/share
![]() |
Period | 2011-06-13 — 2011-06-14 |
![]() |
Region | United States (USA) |
![]() |
Money taker | Danaher Corporation |
| Group | Danaher (Group) | |
![]() |
Product | laboratory equipment and instruments |
| Index term 2 | Beckman Coulter–Danaher: investment, 201102–201106 acqusition cash tender offer $6.8b $83.5/share announced | |
Danaher Corporation. (6/14/11). "Press Release: Danaher Announces Pricing of Public Offering of Its Common Stock". Washington, DC.
Danaher Corporation (NYSE:DHR) announced today that it has set the price for its public offering of 17,500,000 shares of common stock, par value $0.01 per share, at a price to the public of $51.75 per share. Danaher has granted the underwriters a 30-day option to purchase up to an additional 1,750,000 shares of common stock.
Danaher expects to receive net proceeds, after expenses and the underwriters' discount and assuming the underwriters' option is not exercised, of approximately $877.4 million. Danaher anticipates using the net proceeds from the offering to pay a portion of the purchase price of the previously announced acquisition of Beckman Coulter, Inc. and for general corporate purposes if any proceeds remain or if the proposed acquisition does not close. The offering is expected to close on June 21, 2011.
Citi, Morgan Stanley & Co. LLC, Barclays Capital Inc. and UBS Securities LLC are acting as joint book-running managers for the offering. Baird, Jefferies & Company, Inc., Banca IMI, Mitsubishi UFJ Securities and Wells Fargo Securities are acting as co-managers.
The public offering is being made pursuant to an effective shelf registration statement on file with the U.S. Securities and Exchange Commission.
The offering of common stock may be made only by means of a prospectus and prospectus supplement. A copy of the prospectus and prospectus supplement relating to the securities can be obtained from Citi at Prospectus Department, Brooklyn Army Terminal, 140 58th Street, 8th Floor, Brooklyn, New York 11220, or by calling 800-831-9146; and from Morgan Stanley & Co. LLC at 180 Varick Street, 2nd Floor, New York, New York 10014, Attention: Prospectus Department, or by calling (866) 718-1649 or by emailing prospectus@morganstanley.com.
This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, Danaher's common stock or any other securities, nor shall there be any sale of securities mentioned in this press release in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
Danaher is a diversified technology leader that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers.
Statements in this release that are not strictly historical, including the statements regarding the public offering of the common stock, the anticipated use of proceeds and the anticipated acquisition of Beckman Coulter, Inc., and any other statements regarding events or developments that we believe or anticipate will or may occur in the future, may be "forward-looking" statements within the meaning of the federal securities laws. There are a number of important factors that could cause actual events to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including our 2010 Annual Report on Form 10-K and our Quarterly Report on Form 10-Q for the first quarter of 2011. These forward-looking statements speak only as of the date of this release and Danaher does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.
Please contact:
Matt R. McGrew
Vice President, Investor Relations
Danaher Corporation
2200 Pennsylvania Ave, NW
Suite 800W
Washington, D.C. 20037
Telephone: (202) 828-0850
Fax: (202) 828-0860
Record changed: 2011-11-25 |
More documents for Danaher (Group)
- [1] AB Sciex. (5/7/12). "Press Release: AB SCIEX Expands TripleTOF Family with Workhorse System for Routine Analysis. AB SCIEX TripleTOF 4600 System Combines Accurate Mass, High Resolution and High Sensitivity for Use by Wider Range of Scientists...
- [2] AB Sciex. (4/17/12). "Press Release: Breakthrough Proteomics Technique SWATH Acquisition Is Made Availabble to the Worldwide Scientific Community. Data-independent SWATH Acquisition on the TripleTOF 5600 System Enables Comprehensive Proteome-wide Quantit...
- [3] AB Sciex. (4/11/12). "Press Release: AB Sciex Announces New Distribution Agreement with Cluster in Serbia and Macedonia". Serbia....
- [4] AB Sciex. (4/5/12). "Press Release: AB Sciex and Phenomenex Develop Food Safety Solution for India. iMethod Application for Pesticide Screening to Help Support India’s Increasing Agricultural Exports". New Delhi....
- [5] Danaher Corporation. (4/4/12). "Press Release: Danaher Corporation Announces Executive Announcement". Washington, DC....
- [6] Beckman Coulter, Inc.. (3/29/12). "Press Release: Beckman Coulter Life Sciences Acquires Blue Ocean Biomedical. Transaction Expands Flow Cytometry Line, Targets Routine Clinical Analyses". Brea, CA....
- [7] AB Sciex. (3/27/12). "Press Release: AB Sciex Announces Academic Partnership Program to Support Biological Research. Focus on Proteomics, Metabolomics and Lipidomics". Framingham, MA....
- [8] AB Sciex. (3/12/12). "Press Release: AB Sciex Broadens Chromatography Solutions Portfolio with New Eksigent UHPLC Systems. Expansion into Analytical Flow LC Delivers Value for Fully Integrated LC/MS/MS Workflows, Complemented by Evolution of microLC". Fr...
- [9] AB Sciex. (3/12/12). "Press Release: AB Sciex Expands Commercial Operations in Brazil. Brazil Commercial Expansion. Mass Spectrometry Industry Leader Goes Direct to Brazil’s Scientific Community with Highly Qualified Sales, Service and Support Team". São...
- [10] AB Sciex. (3/6/12). "Press Release: AB Sciex Opens New Asia Pacific Application and Training Centre in Singapore’s Biomedical Hub". Singapore....
To subscribe to our free, monthly [MSC] Newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
NEW: Visit our brand new forthcoming web portals Life-Sciences-Germany.com and Life-Sciences-Europe.com
» top
![[MSC] Mass-Spec-Capital.com The Mass Spectrometry Web Portal](/images/basics/msc-mass-spectrometry-portal-logo.jpg)









![Banner [iiito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)